UNITY Biotechnology to Host Investor Call to Review Data from the UBX1325 Program and Provide an Overview of the ENVISION Wet AMD Study
8:00 am ET February 9, 2023 (Globe Newswire)
-Investor call with retinal expert Robert B. Bhisitkul, M.D., Ph.D., to be held on Tuesday, February 14, 2023 at 7:00 a.m. PT/ 10:00 a.m. ET-
-Complete 16- and 24-week safety and efficacy data from phase 2 ENVISION study in wet AMD expected in Q1 2023-
SOUTH SAN FRANCISCO, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that it will host an investor call to discuss lead program, UBX1325, as a potential treatment solution to address the unmet medical need present in age-related diseases of the eye on Tuesday, February 14, 2023 at 7:00 a.m. PT/ 10:00 a.m. ET. Robert B. Bhisitkul, M.D., Ph.D., of University of California San Francisco School of Medicine will review data from the Phase 2 BEHOLD study in diabetic macular edema, followed by an update on upcoming data readouts from the Phase 2 ENVISION study in patients with wet age-related macular degeneration. The Company expects to have 16- and 24-week safety and efficacy data from the ENVISION study in the first quarter of 2023.
A live question and answer session will follow the formal presentation. The webcast can be accessed in the "Investors and Media" section of our website, www.unitybiotechnology.com, under "Events & Presentations" or by clicking here. A replay will be available two hours after the completion of the call and can be accessed in the "Investors & Media" section of our website, under "Events and Presentations."
About UNITY
UNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY's current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn.
Recent UBX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/06/2024 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/06/2024 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/06/2024 09:00:03 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 08:31:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 08:30:09 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 09:04:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 09:00:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 09:05:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 09:05:23 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/11/2023 05:15:29 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/08/2023 09:39:06 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/06/2023 10:25:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 12:00:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/03/2023 08:05:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2023 08:05:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/27/2023 11:05:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/15/2023 08:08:25 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/15/2023 08:07:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2023 08:05:02 PM
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM
Swifty Global Reports Strong Q2 Performance and Prepares for Major Exchange Uplisting • DRCR • Aug 15, 2024 9:04 AM
Mayback's Global Entertainment Signs Global Distribution Agreement with Children's Media Studio • AHRO • Aug 15, 2024 8:45 AM
POET Technologies Reports Second Quarter 2024 Financial Results • POET • Aug 15, 2024 8:04 AM